NCI-Funded Device Start-Ups Offer Game-Changing Technologies

Article preview from Medtech Insight - August, 2012

At the NCI SBIR 2012 Investor Forum, a select group of SBIR grant-funded emerging cancer device companies presented promising next-generation technologies poised to dramatically impact survival from a variety of cancers, including deadly lung, liver, and esophageal malignancies.

NCI-Funded Device Start-Ups Offer Game-Changing Technologies

Article preview from Medtech Insight - August, 2012

Cancer is a formidable, unpredictable set of diseases, and despite decades of expensive research has managed to stay one step ahead of scientists trying to find a cure. Death rates from cancer overall have declined only slightly from the levels seen 60 years ago: 193.9 cancer deaths per 100,000 Americans occurred in 1950, and as of 2010 this figure was 186.2, according to the American Cancer Society. However, research on this complex disease is entering a new era, with recent advances in molecular science and genetics helping to identify distinct cancer “signatures” that can help predict which patients are most likely to benefit from specific drug therapies, aiding development of targeted drugs to match the unique molecular and genetic make-up of individual patients’ tumors, and ushering in new strategies for dealing with troubling metastatic disease. This new knowledge is also being put to use in next-generation device technology, including highly sensitive detection devices and diagnostic tests, drug-eluting implants, and the measurement of disease metastasis and progression by circulating tumor cell (CTC) capture, among many other innovations.

A number of these potentially "game-changing" devices are now advancing toward commercialization, with some of the most promising being developed by an innovative group of young companies that presented this past spring in Santa Clara, CA, at the fourth annual National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Investor Forum. Nearly 200 investors, venture capitalists, strategic partners, and business leaders from the biotech, pharmaceutical, and medical device industries convened for the event, held at the headquarters of Agilent Technologies Inc., and 18 hand-selected, National Cancer Institute SBIR–funded companies provided a "sneak peek" at technologies that are poised to dramatically impact survival from a variety of cancers, including deadly lung, liver, and esophageal malignancies. A review panel of some 65 life science investment and business development experts chose the presenters, out of a field of more than 100 applicants worldwide, as representing the strongest, most promising cancer innovators. Reviewers represented leading cancer players, such as Merck & Co. Inc., Pfizer Inc., Siemens AG, Lilly Ventures Management Co. LLC, Intuitive Surgical Inc., Johnson & Johnson Development Corp., Genentech Inc./Roche, Ventana Medical Systems Inc./Roche, BD Biosciences/Becton Dickinson & Co., and many others.

Continued...

To read this article in its entirety, purchase now, as a PDF and recieve it immediately via email. Or get it free when you subscribe to Medtech Insight Newsletter.

About Medtech Insight

Medtech Insight  newsletter provides insights into the technology and market developments (devices, instrumentation, biomaterials, gene therapy, tissue engineering, etc) impacting a wide range of  surgical and non-surgical clinical practices.